DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain

Information source: Faculdade de Medicina do ABC
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cancer; Pain; Palliative Care

Intervention: Methadone plus Acetaminophen or Placebo (Drug)

Phase: Phase 2/Phase 3

Status: Recruiting

Sponsored by: Faculdade de Medicina do ABC

Official(s) and/or principal investigator(s):
Daniel IG Cubero, Principal Investigator, Affiliation: Faculdade de Medicina do ABC
Auro del Giglio, Study Director, Affiliation: Faculdade de Medicina do ABC

Overall contact:
Daniel IG Cubero, MD, Phone: 55-11-81799103, Email: danielcubero@uol.com.br

Summary

The purpose of this study is to determine whether oral methadone plus acetaminophen can substitute morphine in the treatment of cancer pain.

Clinical Details

Official title: Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain: A Randomized, Double-Blind Study

Study design: Supportive Care, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Pain intensity and time to equianalgesic effect

Secondary outcome: Degree of nausea, vomiting, obstipation, xerostomia and drowsiness

Detailed description: Opioids are the mainstay of moderate-to-severe cancer pain management. Although morphine is the most commonly used, methadone has some advantages such as higher potency, lower cost and longer administration intervals. To minimize the time necessary to achieve the equianalgesic effect after a switching from morphine to methadone, acetaminophen was added in the treatment.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Clinical diagnosis of cancer pain

- Regular use of oral Morphine

Exclusion Criteria:

- Use of Acetaminophen in the last 48 hours

- Renal or Hepatic failure

Locations and Contacts

Daniel IG Cubero, MD, Phone: 55-11-81799103, Email: danielcubero@uol.com.br

Disciplina de Oncologia, Faculdade de Medicina do ABC, Santo André, São Paulo 09060-650, Brazil; Recruiting
Auro del Giglio, Professor, Phone: 55-11-49935491, Email: sandrabr@netpoint.com.br
Daniel IG Cubero, MD, Principal Investigator
Additional Information

Newsletter, March 2004

Starting date: February 2006
Ending date: October 2007
Last updated: September 5, 2007

Page last updated: October 19, 2009

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009